| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl l-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection
|
Youle, M
|
|
2007
|
8 |
4 |
p. 241-250
|
artikel
|
| 2 |
Concomitant use of gastric acid-reducing agents is frequent among HIV-1-infected patients receiving protease inhibitor-based highly active antiretroviral therapy *
|
van Lunzen, J
|
|
2007
|
8 |
4 |
p. 220-225
|
artikel
|
| 3 |
Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Δ32 deletion
|
Laurichesse, JJ
|
|
2007
|
8 |
4 |
p. 213-219
|
artikel
|
| 4 |
Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area
|
Martínez, E
|
|
2007
|
8 |
4 |
p. 251-258
|
artikel
|
| 5 |
Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study *
|
Mallolas, J
|
|
2007
|
8 |
4 |
p. 226-233
|
artikel
|
| 6 |
Multivitamin supplementation in HIV-positive pregnant women: impact on depression and quality of life in a resource-poor setting
|
Smith Fawzi, MC
|
|
2007
|
8 |
4 |
p. 203-212
|
artikel
|
| 7 |
Prediction of clinical benefits of ritonavir-boosted TMC114 from treatment effects on CD4 counts and HIV RNA
|
Hill, A
|
|
2007
|
8 |
4 |
p. 234-240
|
artikel
|
| 8 |
Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials
|
Hill, A
|
|
2007
|
8 |
4 |
p. 259-264
|
artikel
|
| 9 |
Seroprevalence of HIV infection in hospitalized paediatric patients at a tertiary care centre in western India
|
Shah, I
|
|
2007
|
8 |
4 |
p. 265-266
|
artikel
|
Tijdschrift beschrijving